SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|
| DANOVAR | 300,200 mg,mg | Film-coated tablet · Oral use | 30 Bottle | SAR 1464.00 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| DESCOVY 200MG/10MG F.C.TABLET | 200,11.2 mg,mg | Film-coated tablet · Oral use | 30 Bottle | SAR 1626.35 | NCE · Prescription | Gilead Sciences International Ltd | Valid |
| DESCOVY 200MG/25MG F.C.TABLET | 200,28 mg,mg | Film-coated tablet · Oral use | 30 Bottle | SAR 1626.35 | NCE · Prescription | Gilead Sciences International Ltd | Valid |
| Divira | 300,200 mg,mg | Tablet · Oral use | 30 Tablet Container | SAR 1366.40 | Generic · Prescription | Saudi Amarox | Valid |
Indications — CHI Daman Drug Formulary
HUMAN IMMUNODEFICIENCY VIRUS
US FDA United States — FDA approvals (Drugs@FDA)
EMA European Union — centrally authorised medicines
Truvada Gilead Sciences Ireland UC · Authorised · authorised 20 Feb 2005 · ATC J05AR03
Therapeutic indication (EMA)
Treatment of HIV-1 infection: Truvada is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults. Truvada is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years. Pre-exposure prophylaxis (PrEP): Truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.
Descovy Gilead Sciences Ireland UC · Authorised · authorised 21 Apr 2016 · ATC J05AR17
Therapeutic indication (EMA)
Descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1).
Therapeutic indication (EMA)
Treatment of HIV-1 infection Emtricitabine/Tenofovir disoproxil Zentiva is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults. Emtricitabine/Tenofovir disoproxil Zentiva is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents. Pre-exposure prophylaxis (PrEP) Emtricitabine/Tenofovir disoproxil Zentiva is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at high risk.
Therapeutic indication (EMA)
Treatment of HIV-1 infection Emtricitabine/tenofovir disoproxil Krka is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults. Emtricitabine/Tenofovir disoproxil Krka is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years (see section 5.1 Pre-exposure prophylaxis (PrEP) Emtricitabine/Tenofovir disoproxil Krka is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.
Emtricitabine/Tenofovir disoproxil Mylan Mylan Pharmaceuticals Limited · Authorised · authorised 16 Dec 2016 · ATC J05AR03
Therapeutic indication (EMA)
Treatment of HIV-1 infection: Emtricitabine/Tenofovir disoproxil Mylan is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults (see section 5.1). Emtricitabine/Tenofovir disoproxil Mylan is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, (see sections 4.2, 4.4 and 5.1). Pre-exposure prophylaxis (PrEP): Emtricitabine/Tenofovir disoproxil Mylan is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at high risk (see sections 4.2, 4.4 and 5.1).
Therapeutic indication (EMA)
Emtricitabine/Tenofovir disoproxil Krka d.d. is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults. Emtricitabine/Tenofovir disoproxil Krka d.d. is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years.
Therapeutic indication (EMA)
Emtricitabine/Tenofovir alafenamide Viatris is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1).
Canada Canada — marketed products (Health Canada)
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| US NADAC | DESCOVY 120-15 MG TABLET | $74.85402 | per EA | 29 Jun 2026 |
| US NADAC | DESCOVY 200-25 MG TABLET | $74.94147 | per EA | 29 Jun 2026 |
| US NADAC | EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 100-150 MG TAB | $10.19448 | per EA | 22 Apr 2026 |
| US NADAC | EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB | $0.52902 | per EA | 23 Sep 2026 |
| US NADAC | TRUVADA 200 MG-300 MG TABLET | $59.70975 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.4.2.5. Fixed-dose combinations of antiretrovirals · core
Contact with or exposure to human immunodeficiency virus; Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.